Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica

Claudio Flores P; Guillermo Conte L; Patricia Fardella B; Daniel Araos H; Jorge Alfaro L; Paola Aravena R; Néstor González G; Milton Larrondo L

Ayuda

Autotrasplante (AT) de progenitores hematopoyéticos en mieloma múltiple: Experiencia clínica

Claudio Flores P ^[1] ; Guillermo Conte L ^[1] ; Patricia Fardella B ^[1] ; Daniel Araos H ^[1] ; Jorge Alfaro L ^[1] ; Paola Aravena R ^[1] ; Néstor González G ^[1] ; Milton Larrondo L ^[1]
1. [1] Universidad de Chile
  
  Universidad de Chile
  
  Santiago, Chile
Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 133, Nº. 8, 2005, págs. 887-893
Idioma: español
Títulos paralelos:
- Autologous transplant (AT) with peripheral-blood stem-cell rescue for multiple myeloma: A clinical experience
Enlaces
- Texto completo
Resumen
- Background:Multiple myeloma is rarely curable. Advances in high dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. Aim: To report our experience with AT in multiple myeloma, between 1994 and 2003. Material and Methods: Retrospective analysis of 20 patients (12 women), with a mean age of 51.1 years. VAD (vincristine, doxorubicin and dexamethasone) was used as initial therapy in 19 patients. High dose cyclophosphamide (11 patients) and variations of VAD regimen (7) associated with granulocyte colony stimulating factor were used for peripheral-blood stem cell harvest. The conditioning regimen consisted of melphalan 200 mg/m² followed by the reinfusion of peripheral-blood stem cells 24 hours later. The median number of CD34 cells infused was 3,3x10(6)/kg. Three patients were subjected to a second auto graft and one to a non-myeloablative transplant. Mean follow up was 35.5 months. Results: Mucositis and febrile neutropenia were common complications. The median number of days for neutrophyl engraftment was 9 (range 8-11) and for platelets, 10 (range 7-13). No patient died. Complete remission was obtained in 60% (12/20), progession-free survival was 30 months and overall median survival, 47 months. Conclusions: The AT with high-dose melphalan is a safe procedure in our hospital, without mortality and engraftment in all the patients. Complete remission and progression free survival were similar to those reported abroad but the overall median survival was lower